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T-CELL LARGE GRANULAR LYMPHOCYTOSIS FOLLOWING AUTOLO-
GOUS STEM CELL TRANSPLANT
Richard, S.1, Golightly, M.1, Gladstone, D.E.1, Spitzer, S.G.1,
Zamkoff, K.W.1 1Stony Brook University Medical Center, Stony Brook,
NY.
T cell large granular lymphocytosis (T-LGL) following autolo-
gous stem cell transplant (ASCT) has not often been reported.
There have been three publications referring to T-LGL develop-
ing after allogeneic SCT and one case report of a case of T-LGL
leukemia occurring after ASCT. Here, we report four patients
transplanted at our institution, who developed a clonal T-LGL
following ASCT. The patients were transplanted for acute myeloid
leukemia and non Hodgkins lymphoma with busulfan based con-
ditioning regimens. One patient had myeloid and platelet non-
engraftment two months post transplant, the others engrafted
normally by D28 but became mildly to moderately pancytopenic
by day 100 without requiring transfusions. A peripheral blood
smear showed increased numbers of large granular lymphocytes
with phenotype CD2, 3, 8, 57 in upto 49% of lymphocyte
gated cells. T cell gene rearrangement study was polyclonal for the
beta chain by Southern Blot and monoclonal for the gamma chain
by polymerase chain reaction in all these patients. A prolonged and
aggressive disease course was noted in the one patient with delayed
engraftment, with platelet transfusion dependency upto six months
post transplant, but the others had an indolent course, and the
pancytopenia gradually resolved in all four. Three of the four
patients continue to be in remission 9-24 months post ASCT.
We contend that 1) clonal lymphocytosis, particularly T-LGL,
following ASCT may not be an uncommon occurrence and may
explain the observed post autologous transplant “slump” in counts
in at least some instances, although other infectious etiologies
should still be pursued. 2) In most patients this may be an indolent
process that may be chronic or self-limited and does not seem to
impair prognosis. 3) We suggest that a heightened awareness of
this condition may be beneﬁcial to explain pancytopenia following
engraftment after ASCT and further attempts may be made to
elucidate the etiology as well as establish the true incidence of this
phenomenon.
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SINGLE-CENTER EXPERIENCE WITH THE EARLY USE OF AMD3100
PLUS G-CSF FOR MOBILIZATION OF HEMATOPOIETIC PROGENITOR
CELLS IN PATIENTS CLASSIFIED AS POOR MOBILIZERS
Roberts, C.H.1, Chung, H.M.1, Candler, K.S.1, Calandra, G.2,
Badel, K.2, McCarty, J.M.1 1BMT Program, Massey Cancer Center,
VCU Medical Center, Richmond, VA; 2AnorMED Inc, Langley, BC,
Canada.
We report a single-center experience with AMD3100, the
SDF-1 inhibitor, in patients treated after failing chemotherapy or
growth factor based mobilization. Patients unable to collect  0.8
E6 CD34/kg in 2 days or 2.0 E6 in 4 days (7, 25%) or unable to
achieve absolute PB CD34/uL  15 and were not pheresed (21,
75%) were deemed as failure for this strategy. The patient popu-
lation included 14 males and 14 females with NHL (15), MM (6),
AML (3) (AML no longer eligible due to possible leukemia mobi-
lization), HD (3) and DSRCT (1), ages 17-76. Patients were
remobilized with GCSF (10ug/kg/day SQ) on days 1-4 plus
AMD3100 day 4 (240ug/kg/day SQ) and continued until goal
reached. Apheresis began on day 5 and continued for a maximum
of 7 days. The average PB CD34/uL for the failed mobilization was
6.1 and for AMD3100 was 24.7. The average fold increase per
patient ranged from 0.86 to 147 (median 4.2-7.5). There was an
average of 4.4 E6 CD34/kg cells collected by all patients (3.9 for
those failing GCSF alone and 4.8 for those failing chemomobili-
zation). 86 % of patients collected  2 E6 CD34/kg. 70 % of
patients collected  4 E6/kg and 71 % of patients collected  2
E6/kg cells in 1 or 2 days of apheresis. The median number of days
to collect  2 E6 was 4 overall, 4 NHL, 2 HD, 3.5 AML and 6 for
MM patients (3 underwent planned tandem transplant requiring 4
E6 cells). The average number of days to collect  2 E6 was 3.96
(range 1-7) and to collect  4 was 2.9 (range 1-6). No serious
adverse events occurred during mobilization. 24/28 patients re-
ceived a transplant. The average number of days to ANC recovery
was 10.6 and to platelet engraftment, 17.1. 5 patients died before 6
months post transplant with 14 patients alive and well. The com-
bination of AMD3100 and GCSF appears to be effective in mobi-
lizing optimal numbers of CD34 cells in patients failing prior
chemotherapy or growth factor stem cell mobilization. This rep-
resents the largest single institution experience using AMD3100 in
a salvage setting. Our results compare favorably with previously
reported outcomes with AMD3100 in multicenter use and against
historical results with repeated chemotherapy or growth factor
mobilization, due perhaps in part to a relatively consistent deﬁni-
tion of mobilization failure and early intervention with this salvage
agent. Our results support the efﬁcacy and safety of the early use of
AMD3100 in patients failing to mobilize or collect sufﬁcient stem
cells for PBSCT.
Comparison of Successful Collections in Multi-Center Study with
Collections at VCU
AMD3100
compassionate
use protocol
patients (115) Overall
successful
collection
failed
mobilization
chemotherapy
 GCSF
VCU
patients
(28)
Overall %
successful
collection
failed
mobilization
chemotherapy
 G-CSF (16)Disease Cytokine G-CSF (11)
NHL 63 53 71 87 60 100
MM 71 75 68 83 80 100
HD 76 75 78 100 100 100
in VCU study successful collection deﬁned as  2E6 CD34/kg
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HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH AUTOLOGOUS
CORD BLOOD UNITS IN TWO PATIENTS WITH SEVERE APLASTIC ANE-
MIA: TIME FOR REASSESSMENT?
Rosenthal, J.1, Bolotin, E.1, Pawlowska, A.1, Falk, P.1, Oliver, C.1,
Forman, S.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Umbilical cord blood units (CBU), which contain a large number
of hematopoietic stem cells (HSC), have been used successfully for
allogeneic transplantation to treat a variety of benign and malig-
nant hematologic disorders as well as genetic inborn errors of
metabolism. It is now considered an acceptable alternative source
for HSC when autologous or HLA-identical HSC are unavailable.
This advance has resulted in the establishment of not-for-proﬁt
and for-proﬁt cord blood banking banks for autologous and allo-
geneic transplantation. There is a wide consensus against private
banking of autologous CBUs for the following reasons: 1) families
may be vulnerable to emotional marketing at the time of birth of a
child; 2) the life-time likelihood of using autologous HSC trans-
plant is low, between1/10,000-1/200,000; 3) empirical evidence
that children will need their own cord blood for future use is
lacking; 4) no evidence of the safety or effectiveness of autologous
CBU transplantation for the treatment of malignant diseases. Two
patients (5 yr old girl and a 9 yr old girl) were diagnosed with
idiopatic severe aplastic anemia (SAA). Both underwent successful
immunosuppressive and myeloablative treatment followed by HSC
transplantation from autologous CBUs. In one patient (5 yr old
girl) this was the ﬁrst line of therapy, and in the second (9 yr old
girl) it was offered after failure of a course of standard immuno-
suppressive therapy. The conditioning therapy consisted of cyclo-
phosphamide and rabbit ATG . There were no severe transplant-
related adverse effects. Myeloid engraftment occurred on days17
and 21 post-transplant, respectively. Platelet engraftment of
20,000/mm3 occurred on days 20 and 31, and 50,000/mm3
on days 36 and 42, respectively. At 8 months and 3 months
post-transplant both patients have normal peripheral counts and do
not require further immunosuppressive therapy. Both had success-
fully re-integrated into the school system. The rapid and unevent-
ful recovery suggests a favorable role for a short course of immu-
nosuppressive therapy and HSC transplant from an autologous
CBU. This may re-open the discussion regarding the value of
cryopreservation of large number of CBUs.
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